Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | DUT | P33316 | 10/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | TYMP | P19971 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26039535 | 0.88 | PKM (0.52) | PKMDUTALDH1A1LMNACRBN | |
| SCHEMBL26034715 | 0.79 | DUT (0.36) | PKMDUTALDH1A1LMNATSHR | |
| SCHEMBL26039881 | 0.76 | MET (0.38) | ALDH1A1LMNATYMP | |
| SCHEMBL26064036 | 0.75 | DUT (0.40) | PKMDUTALDH1A1LMNACRBN | |
| SCHEMBL24205062 | 0.75 | DUT (0.43) | DUTTSHRCRBN | |
| SCHEMBL26035122 | 0.73 | TSHR (0.43) | DUTTSHR | |
| SCHEMBL26035129 | 0.73 | TSHR (0.43) | DUTTSHR | |
| SCHEMBL26035127 | 0.73 | TSHR (0.43) | DUTTSHR | |
| SCHEMBL24205366 | 0.73 | THRB (0.41) | DUTTSHRCRBN | |
| SCHEMBL26035119 | 0.73 | TSHR (0.43) | DUTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | JOHNSON & JOHNSON SURGICAL VISION INC (US) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230273456-A1 | OPTICALLY ACTIVE DEVICES | PDE6C, PDE6D, PDE6A | PKM 2089/4885DUT 1190/4885ALDH1A1 277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.